Providing quality care requires understanding the disease factors, clinical presentation, and management strategies for immunotherapy-induced cytokine release syndrome with acute lymphoblastic leukemia treatment.

An overview of the clinical presentation, management approaches, and clinical practice guidelines for immunotherapy-related neurotoxicity in acute lymphoblastic leukemia treatment is presented.

Clinicians should recognize the prognostic importance of minimal residual disease testing and its implications for treatment pathways in acute lymphoblastic leukemia.

Navigating the complexities of acute lymphoblastic leukemia treatment requires a multidisciplinary team approach to the management of multiple care needs in inpatient and outpatient settings.

Successful transitions of care from the hospital to the home setting for patients with acute lymphoblastic leukemia requires a team of hospital and outpatient clinicians to provide coordinated care and support.